The review estimated about four additional diagnoses of gastroesophageal reflux disease per 1,000 people treated, compared with placebo [1]. That figure describes the difference in risk, rather than the total number of people who developed reflux.
What was pooled
Our GLP-1 side-effect guide covers common symptoms such as nausea. This review searched five databases for placebo-controlled randomized trials that reported specific gastrointestinal and biliary events in type 2 diabetes, overweight or obesity, and fatty liver disease. It included 55 trials and 106,395 participants [1].
Two things went up
Gallstones. The risk ratio was 1.46, 95% CI 1.09 to 1.97, which the authors translate as about 2 extra cases per 1,000 people treated. Reflux. The risk ratio was 2.19, 95% CI 1.48 to 3.25, or about 4 extra cases per 1,000.
The 46% relative increase in gallstone risk corresponded to about two extra cases per 1,000 people at the baseline risk used in this review. Our gallbladder risk guide explains why estimates differ across outcomes and studies. A person's baseline risk affects the absolute difference.
What the review found for other outcomes
The authors judged that treatment probably had little or no effect on the other outcomes they studied, including pancreatitis, bowel obstruction, gastrointestinal bleeding and gastroparesis.
Rare events can be hard to measure even across many trials. The pooled results leave uncertainty about how much risk changes for some outcomes.
What to check about follow-up care
Our guide to advertised and billed prices explains why a medication quote and the cost of clinical care can differ. Ask who handles new symptoms during treatment and whether follow-up visits carry a separate charge.